subject:(Hepatitis C)

University of Georgia

1. Sims, Omar Tremayne. An epidemiologic longitudinal analysis on the management of neuropsychiatric side effects with selective serotonin reuptake inhibitors (SSRIS) during hepatitis C antiviral therapy on a cohort of chronic hepatitis C patients: implications for sustained virological responses and quality of life.

Degree: PhD, Social Work, 2011, University of Georgia

URL: http://purl.galileo.usg.edu/uga_etd/sims_omar_t_201108_phd

► Epidemiologists estimate hepatitis C viral infection (HCV) is the most common blood-borne viral infection in the United States and most of the western world. Pegylated… (more)

▼ Epidemiologists estimate hepatitis C viral infection (HCV) is the most common blood-borne viral infection in the United States and most of the western world. Pegylated interferon in combination with ribavirin is the standard of care for HCV. Though an effective pharmacological agent for HCV viral suppression, pegylated interferon induces neuropsychiatric side effects that culminate in a psychiatric disorder known as interferon induced major depressive disorder. Selective serotonin reuptake inhibitors (SSRIs) are widely used during HCV antiviral therapy to prevent or alleviate neuropsychiatric morbidity associated with pegylated interferon. However, it is unclear whether the anti-inflammatory properties of SSRIs inadvertently work against the pro-inflammatory properties of pegylated interferon in effect reducing the therapeutic efficacy of HCV antiviral therapy. The purpose of this study is to determine the effects of SSRIs and interferon induced major depressive disorder on sustained virological responses and quality of life in a cohort of HCV patients (n=46). Patients with active psychiatric disorders are included in the cohort. The study design is a longitudinal retrospective cohort design with a cross-sectional survey. Quantitative methods consist of an epidemiologic longitudinal analysis of a cohort of HCV patients who have previously undergone and completed pegylated interferon combination therapy. The measurements for the independent variables are SSRI use and interferon induced major depressive disorder, and HCV viral logs for the dependent variable. Generalized estimating equations (GEE) are used to determine the effects of SSRI therapy and interferon induced major depressive disorder on HCV viral logs over time. Qualitative methods consist of semi-structured interviews to compliment the quantitative findings. In this cohort, SSRI therapy and interferon induced major depressive disorder does not impact the probability of HCV patients achieving a sustained virological response. However, the mean slope of HCV viral logs decline faster over time in patients with interferon induced major depressive disorder in comparison to patients without interferon induced major depressive disorder (p=0.05). This finding suggests interferon induced major depressive disorder patients achieve sustained virological responses faster or suppress HCV viral replication more favorably over time during HCV antiviral therapy. Implications for treatment and management of HCV are discussed. Advisors/Committee Members: Larry Nackerud.

Subjects/Keywords: Hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Sims, O. T. (2011). An epidemiologic longitudinal analysis on the management of neuropsychiatric side effects with selective serotonin reuptake inhibitors (SSRIS) during hepatitis C antiviral therapy on a cohort of chronic hepatitis C patients: implications for sustained virological responses and quality of life. (Doctoral Dissertation). University of Georgia. Retrieved from http://purl.galileo.usg.edu/uga_etd/sims_omar_t_201108_phd

Chicago Manual of Style (16^th Edition):

Sims, Omar Tremayne. “An epidemiologic longitudinal analysis on the management of neuropsychiatric side effects with selective serotonin reuptake inhibitors (SSRIS) during hepatitis C antiviral therapy on a cohort of chronic hepatitis C patients: implications for sustained virological responses and quality of life.” 2011. Doctoral Dissertation, University of Georgia. Accessed February 25, 2020. http://purl.galileo.usg.edu/uga_etd/sims_omar_t_201108_phd.

MLA Handbook (7^th Edition):

Sims, Omar Tremayne. “An epidemiologic longitudinal analysis on the management of neuropsychiatric side effects with selective serotonin reuptake inhibitors (SSRIS) during hepatitis C antiviral therapy on a cohort of chronic hepatitis C patients: implications for sustained virological responses and quality of life.” 2011. Web. 25 Feb 2020.

Vancouver:

Sims OT. An epidemiologic longitudinal analysis on the management of neuropsychiatric side effects with selective serotonin reuptake inhibitors (SSRIS) during hepatitis C antiviral therapy on a cohort of chronic hepatitis C patients: implications for sustained virological responses and quality of life. [Internet] [Doctoral dissertation]. University of Georgia; 2011. [cited 2020 Feb 25]. Available from: http://purl.galileo.usg.edu/uga_etd/sims_omar_t_201108_phd.

Council of Science Editors:

Sims OT. An epidemiologic longitudinal analysis on the management of neuropsychiatric side effects with selective serotonin reuptake inhibitors (SSRIS) during hepatitis C antiviral therapy on a cohort of chronic hepatitis C patients: implications for sustained virological responses and quality of life. [Doctoral Dissertation]. University of Georgia; 2011. Available from: http://purl.galileo.usg.edu/uga_etd/sims_omar_t_201108_phd

University of Hong Kong

2. Yuen, King-tai. A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV.

Degree: Master of Medical Sciences, 2013, University of Hong Kong

URL: Yuen, K. [袁敬弟]. (2013). A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5091621 ; http://dx.doi.org/10.5353/th_b5091621 ; http://hdl.handle.net/10722/193555

►

The cost effectiveness of using novel HCV treatment option, telaprevir and boceprevir, should depend on patients’ respond to conventional PEG-INFα and ribavirin therapy. The study… (more)

▼

The cost effectiveness of using novel HCV treatment option, telaprevir and boceprevir, should depend on patients’ respond to conventional PEG-INFα and ribavirin therapy. The study of pharmacogenomics, interleukin-28B (IL-28B) polymorphisms, accompanied with the information of HCV genotypes are suggested to have the strongest predictive value of treatment outcomes and prognosis of disease in individuals infected with HCV who are undergoing conventional PEG-INFα and ribavirin therapy. It is extremely valuable in HCV/HIV co-infected patients as these groups of patients require a complex treatment regimen and demonstrate poor sustained viral response (SVR) rate. The development of a fast and promising IL-28B genotyping assay is urgently needed. A total of 47 blood samples randomly selected from HCV and HIV co-infected patients were used in this investigation. The aims of this study are to evaluate and compare the performance of newly developed IL-28B HybProbe real-time PCR assay using LightCycler® system against Sanger Sequencing method in determining IL-28B polymorphisms on rs12979860 and rs8099917 and to estimate the prevalence of IL-28B polymorphisms among HCV/HIV co-infected patients in Hong Kong. In addition, the genotypic distribution of HCV among the same patient group is identified by using in-house Sanger Sequencing method. It was found that the newly developed IL-28B real-time HybProbe assay resulted in 100% concordance with the traditionally used Sanger Sequencing method. The allele frequencies of C and T were 96% and 4% in rs12979860 and T and G were 97% and 3% in rs8099917 respectively. The CC and TT wild type are predominating in rs12979860 and rs8099917 with frequencies of 93.62% and 95.74% respectively. The most favorable compound genotype CC/TT with both homozygous wild types on both SNPs was the most predominant type with a high prevalence of 93.61%. Among all the samples, 50% samples were found to be HCV genotype 1, 41.18% were genotype 6 and 8.82% were genotype 3. A simple and efficient IL-28B real-time HybProbe assay was developed in this study and proved to show excellent performance on IL-28B genotyping although further optimization is suggested before it can be applied in the clinical setting. The favourable wild type genotypes of rs12979860 and rs8099917 accounted for the most predominant genotypes which is similar to other findings obtained from an Asian population. A comparatively high prevalence of HCV genotype 6 was found in the HCV/HIV co-infected group. Future study with the information of treatment outcomes (HCV viral load) can further evaluate the predictive value of IL-28B polymorphisms on SVR in different HCV genotypes.

published_or_final_version

Medical Sciences

Master

Master of Medical Sciences

Subjects/Keywords: Hepatitis C - Treatment; Hepatitis C - Prognosis

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Yuen, K. (2013). A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV. (Masters Thesis). University of Hong Kong. Retrieved from Yuen, K. [袁敬弟]. (2013). A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5091621 ; http://dx.doi.org/10.5353/th_b5091621 ; http://hdl.handle.net/10722/193555

Chicago Manual of Style (16^th Edition):

Yuen, King-tai. “A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV.” 2013. Masters Thesis, University of Hong Kong. Accessed February 25, 2020. Yuen, K. [袁敬弟]. (2013). A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5091621 ; http://dx.doi.org/10.5353/th_b5091621 ; http://hdl.handle.net/10722/193555.

MLA Handbook (7^th Edition):

Yuen, King-tai. “A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV.” 2013. Web. 25 Feb 2020.

Vancouver:

Yuen K. A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV. [Internet] [Masters thesis]. University of Hong Kong; 2013. [cited 2020 Feb 25]. Available from: Yuen, K. [袁敬弟]. (2013). A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5091621 ; http://dx.doi.org/10.5353/th_b5091621 ; http://hdl.handle.net/10722/193555.

Council of Science Editors:

Yuen K. A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV. [Masters Thesis]. University of Hong Kong; 2013. Available from: Yuen, K. [袁敬弟]. (2013). A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5091621 ; http://dx.doi.org/10.5353/th_b5091621 ; http://hdl.handle.net/10722/193555

Texas A&M University

3. Klemashevich, Cory. Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus.

Degree: 2013, Texas A&M University

URL: http://hdl.handle.net/1969.1/149463

► Up to 170 million people are infected with Hepatitis C Virus worldwide. Chronic HCV infection is the leading cause of fibrosis, cirrhosis and liver cancer.… (more)

Subjects/Keywords: Hepatitis C; Dihydropyridine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Klemashevich, C. (2013). Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus. (Thesis). Texas A&M University. Retrieved from http://hdl.handle.net/1969.1/149463

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Klemashevich, Cory. “Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus.” 2013. Thesis, Texas A&M University. Accessed February 25, 2020. http://hdl.handle.net/1969.1/149463.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Klemashevich, Cory. “Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus.” 2013. Web. 25 Feb 2020.

Vancouver:

Klemashevich C. Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus. [Internet] [Thesis]. Texas A&M University; 2013. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/1969.1/149463.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Klemashevich C. Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus. [Thesis]. Texas A&M University; 2013. Available from: http://hdl.handle.net/1969.1/149463

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Hong Kong

4. 陳西寧; Chan, Sai-ning. Budget impact analysis of newly available treatments for chronic hepatitis C infection in Hong Kong.

Degree: Master of Medical Sciences, 2016, University of Hong Kong

URL: http://hdl.handle.net/10722/237266

►

Background Hepatitis C is a global public health issue causing 3-4 million new infections each year. Revolutionary change of treatment landscape is underway with approval… (more)

▼

Background Hepatitis C is a global public health issue causing 3-4 million new infections each year. Revolutionary change of treatment landscape is underway with approval of second generation direct-acting antivirals (DAAs) which possess remarkable safety, efficacy and tolerability. In Hong Kong, Sofosbuvir (SOF), Ledipasvir/Sofosbuvir (LED/SOF) and Ombitasvir/Paritaprevir/ Ritonavir plus Dasabuvir (VP) are registered; SOF and VP are listed as special drugs in Hospital Authority (HA) Drug Formulary. However, local pharmacoeconomic study is yet to be established to evaluate the cost impact of new DAAs. Objective The goal of this study is to evaluate the budget impact of SOF, LED/SOF and VP treatments to the Hong Kong healthcare system from the HA perspective, as well as the benefits of adding LED/SOF to the formulary. Method Prevalence and incidence of genotype 1 hepatitis C infection in Hong Kong were estimated using local and overseas data. Budget impact analysis was conducted under best scenario – treating all prevalent patients in the first year and incident patients in subsequent years. 5-year time horizon was adopted. Individual treatment cost was compared with standard of care (Boceprevir, BOC treatment) and between new DAAs; total expenditure and clinical management costs incurred with and without introduction of new DAAs were also compared. Results Prevalent population was estimated to be 12,674 in 2016 and incident population was 304 per year in 2017-2020. Comparing with BOC treatment, new DAA treatments present cost-saving manner in treatment cost per SVR (sustained virologic response) of individual treatment, clinical management costs, total cost (5,571 vs. 5,540 million) and total cost per SVR (8,892 vs. 6,004 million) over the 5 years. Over 90% of total expenditure occurred in the first year under the best scenario. Sensitivity analysis assessed cost variance due to variation in cost ratio, market share of drugs, proportion of treatment experienced and SVR of drugs. VP would be the most “budget friendly” DAA, followed by LED/SOF as both DAAs would cause additional reduction in total cost per SVR when increase in market share. Conclusion Lower treatment cost per SVR and total costs suggested cost-saving from introduction of new DAAs to the formulary. Moreover, listing LED/SOF to the formulary would be beneficial to total cost per SVR and clinical management costs, and provide patients of other genotype infection with equitable access of optimal treatment. Further studies on other HCV genotypes, recently approved DAAs and cost impact from reduced risk of liver complications are required in order to assess the overall budget impact of newly available hepatitis C treatments.

published_or_final_version

Pharmacology and Pharmacy

Master

Master of Medical Sciences

Subjects/Keywords: Hepatitis C - Treatment

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

陳西寧; Chan, S. (2016). Budget impact analysis of newly available treatments for chronic hepatitis C infection in Hong Kong. (Masters Thesis). University of Hong Kong. Retrieved from http://hdl.handle.net/10722/237266

Chicago Manual of Style (16^th Edition):

陳西寧; Chan, Sai-ning. “Budget impact analysis of newly available treatments for chronic hepatitis C infection in Hong Kong.” 2016. Masters Thesis, University of Hong Kong. Accessed February 25, 2020. http://hdl.handle.net/10722/237266.

MLA Handbook (7^th Edition):

陳西寧; Chan, Sai-ning. “Budget impact analysis of newly available treatments for chronic hepatitis C infection in Hong Kong.” 2016. Web. 25 Feb 2020.

Vancouver:

陳西寧; Chan S. Budget impact analysis of newly available treatments for chronic hepatitis C infection in Hong Kong. [Internet] [Masters thesis]. University of Hong Kong; 2016. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/10722/237266.

Council of Science Editors:

陳西寧; Chan S. Budget impact analysis of newly available treatments for chronic hepatitis C infection in Hong Kong. [Masters Thesis]. University of Hong Kong; 2016. Available from: http://hdl.handle.net/10722/237266

University of Plymouth

5. Mandalou, Paraskevi. Molecular mechanisms of protection from hepatitis C infection.

Degree: Thesis (M.D.), 2018, University of Plymouth

URL: http://hdl.handle.net/10026.1/11610

► Hepatitis C virus (HCV) infection is a major global health burden affecting 1-2% of the world’s population. The majority of infected individuals will develop chronic… (more)

▼ Hepatitis C virus (HCV) infection is a major global health burden affecting 1-2% of the world’s population. The majority of infected individuals will develop chronic infection and are at risk of cirrhosis and hepatocellular carcinoma. There is currently no preventative vaccine available for HCV. In the developed world, the highest HCV incidence and prevalence rate is amongst intravenous drug users (IDU). The duration, frequency of IDU, and sharing of drug injecting equipment contribute to particularly high rates of HCV infection in this population. Individuals at high risk of recurrent exposure to HCV infection from long term IDU have been recruited in Plymouth, UK, from 2003 onwards and if they remain negative for HCV infection are termed exposed uninfected (EU). Understanding the factors that prevent HCV infection in this cohort could give valuable insight into the mechanisms of natural resistance to HCV infection. The EU cohort was previously shown to have characteristics attributable to the activation of both the adaptive and the innate arms of the immune system with no known dominant, immune or non- immune, mechanism of HCV protection. The aim of this thesis was to attempt and identify this mechanism and for that purpose a comparative transcriptional profile study was initially performed between 3 groups: EU, individuals who spontaneously cleared HCV infection (SR) and patients with chronic HCV infection (CHCV). Of the differentially regulated genes, the association with resistance to HCV was strongest for Interleukin-27 (IL-27) which was significantly upregulated in EU compared to the 2 other groups and C X C motif chemokine 7 (CXCL7) which was significantly upregulated in EU relative to the CHCV group. The CD28 mediated T-helper cell signalling pathway was significantly upregulated in SR relative to the 2 other groups. We attempted to corroborate the above findings and we demonstrated that IL-27 is overexpressed in EU, compared to SR and CHCV. The possible role of IL-27 in natural protection from HCV infection remains to be elucidated and requires further study.

Subjects/Keywords: Hepatitis C; Vaccine for hepatitis C; Immunology of hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Mandalou, P. (2018). Molecular mechanisms of protection from hepatitis C infection. (Doctoral Dissertation). University of Plymouth. Retrieved from http://hdl.handle.net/10026.1/11610

Chicago Manual of Style (16^th Edition):

Mandalou, Paraskevi. “Molecular mechanisms of protection from hepatitis C infection.” 2018. Doctoral Dissertation, University of Plymouth. Accessed February 25, 2020. http://hdl.handle.net/10026.1/11610.

MLA Handbook (7^th Edition):

Mandalou, Paraskevi. “Molecular mechanisms of protection from hepatitis C infection.” 2018. Web. 25 Feb 2020.

Vancouver:

Mandalou P. Molecular mechanisms of protection from hepatitis C infection. [Internet] [Doctoral dissertation]. University of Plymouth; 2018. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/10026.1/11610.

Council of Science Editors:

Mandalou P. Molecular mechanisms of protection from hepatitis C infection. [Doctoral Dissertation]. University of Plymouth; 2018. Available from: http://hdl.handle.net/10026.1/11610

University of Zambia

6. Nchimba, Lweendo. Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia .

Degree: 2015, University of Zambia

URL: http://hdl.handle.net/123456789/3726

► Background: Sickle Cell Disease (SCD) is highly prevalent in Africans. The SCD trait is 18% in the general population in Zambia and University Teaching Hospital… (more)

▼ Background: Sickle Cell Disease (SCD) is highly prevalent in Africans. The SCD trait is 18% in the general population in Zambia and University Teaching Hospital in Lusaka has under its care over 1500 SCD patients. SCD causes high morbidity and mortality. Patients with SCD often have pathologies that require a blood transfusion. Specific indications for blood transfusion in SCD include acute splenic sequestration, aplastic crises, cardiopulmonary symptoms or signs (e.g. high-output heart failure or hypoxemia), preoperative use, priapism, and life-threatening events that would benefit from improved oxygen delivery such as sepsis, severe infection, acute chest syndrome, stroke, and acute organ ischemia. In addition, blood transfusion remains the first-line therapy for primary and secondary stroke prevention in children with SCD. Transfusion is usually performed when haemoglobin is less than five g/dL. Both hepatitis B and C are blood-borne and therefore can be transmitted by blood transfusion. SCD patients are a special population that requires frequent blood transfusions. Thus, they are prone to acquiring hepatitis B and C. Screening services have greatly reduced the risk of infection via blood transfusion, but transmissions still occur. Methods: A cross-sectional study was done to determine the prevalence of hepatitis B (HBV) and / or hepatitis C (HCV) infection in the SCD population at UTH in Lusaka. Basic demographic characteristics, medical information and laboratory data were collected and used to determine the predictors for hepatitis B and HCV infections in SCD children and adults. A total of 138 patients were screened for Hepatitis B surface antigen, which is a marker for HBV infection, as well as for hepatitis C antibody, the surrogate marker for HCV infection. Human-immuno-deficiency virus or HIV testing was done on all the samples.Findings: Fifty-nine percent of the participants enrolled were female. The mean age at diagnosis was 2years 9 months ± 2.5. The mean haemoglobin level was 7.2g/dL. Only 37% had confirmation of SCD diagnosis on their medical record. HBV prevalence amongst the SCD is 2.2%. Its prevalence is not associated with blood transfusions, age, tattoos or gender. It has a non-significant association with increasing age and sexual activity. HBV infection has been markedly reduced due to vaccination introduced in 2005 in Zambia. The prevalence of HCV is 0.7% and could not be subjected to much statistical manipulation. Conclusion: HBV prevalence amongst the SCD is 2.2%. Its prevalence was not associated with increase in number of blood transfusions. There was a non-significant association between HBV prevalence and increase in age as well as sexual activity. The prevalence of HCV is 0.7%.

Subjects/Keywords: Sickle-Cell Anemia; Hepatitis B; Hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Nchimba, L. (2015). Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia . (Thesis). University of Zambia. Retrieved from http://hdl.handle.net/123456789/3726

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Nchimba, Lweendo. “Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia .” 2015. Thesis, University of Zambia. Accessed February 25, 2020. http://hdl.handle.net/123456789/3726.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Nchimba, Lweendo. “Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia .” 2015. Web. 25 Feb 2020.

Vancouver:

Nchimba L. Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia . [Internet] [Thesis]. University of Zambia; 2015. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/123456789/3726.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Nchimba L. Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia . [Thesis]. University of Zambia; 2015. Available from: http://hdl.handle.net/123456789/3726

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Hong Kong

7. 李妙珊.; Li, Miu-shan. Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong.

Degree: Master of Medical Sciences, 2012, University of Hong Kong

URL: Li, M. [李妙珊]. (2012). Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4833416 ; http://dx.doi.org/10.5353/th_b4833416 ; http://hdl.handle.net/10722/173852

►

Hepatitis C Virus “HCV” is the major factor to develop the chronic liver disease. Accurate genotyping is important to decide the choice and duration of… (more)

Subjects/Keywords: Hepatitis C virus - Genetics.

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

李妙珊.; Li, M. (2012). Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong. (Masters Thesis). University of Hong Kong. Retrieved from Li, M. [李妙珊]. (2012). Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4833416 ; http://dx.doi.org/10.5353/th_b4833416 ; http://hdl.handle.net/10722/173852

Chicago Manual of Style (16^th Edition):

李妙珊.; Li, Miu-shan. “Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong.” 2012. Masters Thesis, University of Hong Kong. Accessed February 25, 2020. Li, M. [李妙珊]. (2012). Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4833416 ; http://dx.doi.org/10.5353/th_b4833416 ; http://hdl.handle.net/10722/173852.

MLA Handbook (7^th Edition):

李妙珊.; Li, Miu-shan. “Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong.” 2012. Web. 25 Feb 2020.

Vancouver:

李妙珊.; Li M. Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong. [Internet] [Masters thesis]. University of Hong Kong; 2012. [cited 2020 Feb 25]. Available from: Li, M. [李妙珊]. (2012). Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4833416 ; http://dx.doi.org/10.5353/th_b4833416 ; http://hdl.handle.net/10722/173852.

Council of Science Editors:

李妙珊.; Li M. Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong. [Masters Thesis]. University of Hong Kong; 2012. Available from: Li, M. [李妙珊]. (2012). Molecular characterization of different subgenomic regions of hepatitis C virus genotype 6 in Hong Kong. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4833416 ; http://dx.doi.org/10.5353/th_b4833416 ; http://hdl.handle.net/10722/173852

University of Minnesota

8. Sweet Kennedy, Kristin. Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment.

Degree: PhD, Health Services Research, Policy and Administration, 2014, University of Minnesota

URL: http://hdl.handle.net/11299/174894

► Hepatitis C (HCV) infection is the most common bloodborne illness in the United States and the prevalence is highest in those born between 1945 and… (more)

Subjects/Keywords: Hepatitis C; Hepatocellular Carcinoma

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Sweet Kennedy, K. (2014). Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment. (Doctoral Dissertation). University of Minnesota. Retrieved from http://hdl.handle.net/11299/174894

Chicago Manual of Style (16^th Edition):

Sweet Kennedy, Kristin. “Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment.” 2014. Doctoral Dissertation, University of Minnesota. Accessed February 25, 2020. http://hdl.handle.net/11299/174894.

MLA Handbook (7^th Edition):

Sweet Kennedy, Kristin. “Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment.” 2014. Web. 25 Feb 2020.

Vancouver:

Sweet Kennedy K. Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment. [Internet] [Doctoral dissertation]. University of Minnesota; 2014. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/11299/174894.

Council of Science Editors:

Sweet Kennedy K. Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment. [Doctoral Dissertation]. University of Minnesota; 2014. Available from: http://hdl.handle.net/11299/174894

University of Newcastle

9. Salmond, Sarah (Ses) Jane. The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C.

Degree: PhD, 2013, University of Newcastle

URL: http://hdl.handle.net/1959.13/1036900

►

Research Doctorate - Doctor of Philosophy (PhD)

Oxidative stress (OS) is a key mechanism by which liver injury occurs in chronic hepatitis C (CHC) virus… (more)

▼

Research Doctorate - Doctor of Philosophy (PhD)

Oxidative stress (OS) is a key mechanism by which liver injury occurs in chronic hepatitis C (CHC) virus infection. For this Study, it was hypothesised the use of antioxidant compounds would reduce OS, hepatic necroinflammation and hepatic fibrosis in CHC patients. To test this hypothesis, a randomised, double-blind, placebo-controlled clinical trial (termed the 'Hep573 Study') was conducted in three Australian teaching hospitals in New South Wales. One hundred and eighteen participants were recruited through the liver outpatient clinics at the hospitals from July, 2003 to March, 2006. They were randomised to treatment in blocks of six to one of three groups: placebo; silymarin (720 mg silybin/day); and silymarin with antioxidants (720 mg silybin plus 13 other ingredients). Study duration was 48 weeks: 24 weeks on active treatment or placebo, and 24 weeks follow-up post treatment. The primary outcome measure was the proportion of patients with alanine aminotransferase (ALT) normalisation at Week 24 (Fisher‟s exact test). Secondary outcome measures were the percentage change from baseline to Week 24 in F₂₋isoprostanes, and to Week 24 and Week 48 in ALT, HCV viral load (HCV RNA) and FibroTest (Linear Mixed Effects). Results were analysed on an intention-to-treat basis. In patients with compensated CHC, the use of silymarin and antioxidant compounds achieved a higher rate of ALT normalisation than placebo (P=0.02) or silymarin (P=0.003) at Week 24. This result could not be attributed to alcohol, diet or caffeine, as intake across the groups did not change throughout the Study. In addition, there was a significant improvement in the overall mental-health score (Mental Component Summary), QualityMetric Hepatitis Quality of Life Questionnaire™ (HQLQ) in the silymarin and antioxidant (SOX) group (P=0.002). This novel randomised, double-blind, placebo-controlled trial of oral silymarin and oral antioxidants has shown a reduction in hepatic necroinflammation and an improvement in overall mental-health status in a specific CHC population.

Advisors/Committee Members: University of Newcastle. Faculty of Health & Medicine, School of Medicine and Public Health.

Subjects/Keywords: silymarin; antioxidants; chronic hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Salmond, S. (. J. (2013). The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C. (Doctoral Dissertation). University of Newcastle. Retrieved from http://hdl.handle.net/1959.13/1036900

Chicago Manual of Style (16^th Edition):

Salmond, Sarah (Ses) Jane. “The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C.” 2013. Doctoral Dissertation, University of Newcastle. Accessed February 25, 2020. http://hdl.handle.net/1959.13/1036900.

MLA Handbook (7^th Edition):

Salmond, Sarah (Ses) Jane. “The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C.” 2013. Web. 25 Feb 2020.

Vancouver:

Salmond S(J. The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C. [Internet] [Doctoral dissertation]. University of Newcastle; 2013. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/1959.13/1036900.

Council of Science Editors:

Salmond S(J. The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C. [Doctoral Dissertation]. University of Newcastle; 2013. Available from: http://hdl.handle.net/1959.13/1036900

University of Saskatchewan

10. Landi, Abdolamir. Human dendritic cells and hepatitis C Virus.

Degree: 2009, University of Saskatchewan

URL: http://hdl.handle.net/10388/etd-01062010-155600

► Dendritic cells (DCs) constitute a large family of immune cells with a dendritic morphology and a critical role in all aspects of an immune response… (more)

▼ Dendritic cells (DCs) constitute a large family of immune cells with a dendritic morphology and a critical role in all aspects of an immune response and immune regulation, from immunogenicity to tolerance. One of the important characteristic of DCs is maturation, during which DCs undergo significant changes in their phenotypic and functional properties and change from phagocytic cells to highly efficient antigen presenting cells (APCs). Dendritic cells have recently been at the centre of attention as a promising tool in treatment or control of cancer and infectious diseases. Accordingly, DCs have been generated, matured, and loaded with tumor-associated or microbial antigens ex vivo, to be subsequently used as therapeutic tools or vaccine carriers. Hepatitis C virus (HCV) is a hepatotropic virus, which infects the liver in humans and results in a chronic infection in most cases. The persistent infection of the liver eventually results in cirrhosis and/or hepatocellular carcinoma in 15-20 years. Chronic hepatitis C (CHC) has recently become a serious health concern and the leading cause of liver transplantation. The mechanism of persistence of the virus is not clear yet, but as a Th1-type immune response is strongly correlated with elimination of HCV in vivo, it is evident that insufficient cellular immunity is a contributing factor. Non-cytopathic viruses such as HCV may infect immune cells to modify and evade a protective immune response. Dendritic cells, which are the most potent APCs, and uniquely capable of initiating a primary immune response, have been considered as a target for HCV. Inhibition of DC maturation by HCV has been suggested as a potential contributing factor in immune evasion; however, this issue remains controversial as many contradictory results have been reported. To investigate this contention, we initially planned to evaluate the effects of HCV on DCs of CHC patients; however, due to limited access to patients’ blood, we instead elected to examine the effects of HCV genes products on in vitro generated DCs from healthy volunteers. Specific attention was paid to the generation, maturation, and transfection of DCs in vitro, as variability in procedures might have been responsible for the controversial reports. Viral vectors have generally been used to transfect DCs; however, a vector and HCV genes might have synergistic effects on DC maturation. Thus, our first objective was to develop an efficient non-viral transfection method while retaining high viability of the DCs, as previous efforts in this regard resulted either in low efficiency or in low viability of DCs after transfection. In order to improve the viability of DCs after transfection, we established a new method for fast generation of monocyte-derived DCs (Mo-DCs) in two to three days. By performing a comprehensive study on transfection reagents, electroporation, and nucleofection with DNA or in vitro transcribed (IVT) RNA, we successfully established a new, highly efficient non-viral method for transfection of DCs with long-term… Advisors/Committee Members: van den Hurk, Sylvia, Babiuk, Lorne A, Qualtiere, Louis, Williams, Kurt, Misra, Vikram, Elliott, John F.

Subjects/Keywords: hepatitis C virus; dendritic cells

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Landi, A. (2009). Human dendritic cells and hepatitis C Virus. (Thesis). University of Saskatchewan. Retrieved from http://hdl.handle.net/10388/etd-01062010-155600

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Landi, Abdolamir. “Human dendritic cells and hepatitis C Virus.” 2009. Thesis, University of Saskatchewan. Accessed February 25, 2020. http://hdl.handle.net/10388/etd-01062010-155600.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Landi, Abdolamir. “Human dendritic cells and hepatitis C Virus.” 2009. Web. 25 Feb 2020.

Vancouver:

Landi A. Human dendritic cells and hepatitis C Virus. [Internet] [Thesis]. University of Saskatchewan; 2009. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/10388/etd-01062010-155600.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Landi A. Human dendritic cells and hepatitis C Virus. [Thesis]. University of Saskatchewan; 2009. Available from: http://hdl.handle.net/10388/etd-01062010-155600

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Victoria

11. Zukowski, Phyllis Donna. Women’s experiences of receiving a diagnosis and living with Hepatitis C.

Degree: School of Nursing, 2011, University of Victoria

URL: http://hdl.handle.net/1828/3595

► This research explores the lived experiences of what it means to women when they receive a diagnosis of Hepatitis C (HCV). The approach to guide… (more)

Subjects/Keywords: Hepatitis C; women; Nursing

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Zukowski, P. D. (2011). Women’s experiences of receiving a diagnosis and living with Hepatitis C. (Masters Thesis). University of Victoria. Retrieved from http://hdl.handle.net/1828/3595

Chicago Manual of Style (16^th Edition):

Zukowski, Phyllis Donna. “Women’s experiences of receiving a diagnosis and living with Hepatitis C.” 2011. Masters Thesis, University of Victoria. Accessed February 25, 2020. http://hdl.handle.net/1828/3595.

MLA Handbook (7^th Edition):

Zukowski, Phyllis Donna. “Women’s experiences of receiving a diagnosis and living with Hepatitis C.” 2011. Web. 25 Feb 2020.

Vancouver:

Zukowski PD. Women’s experiences of receiving a diagnosis and living with Hepatitis C. [Internet] [Masters thesis]. University of Victoria; 2011. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/1828/3595.

Council of Science Editors:

Zukowski PD. Women’s experiences of receiving a diagnosis and living with Hepatitis C. [Masters Thesis]. University of Victoria; 2011. Available from: http://hdl.handle.net/1828/3595

University of Adelaide

12. Jagdale, Harshwardhan. Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus.

Degree: 2016, University of Adelaide

URL: http://hdl.handle.net/2440/112856

► Hepatitis C virus (HCV) infects over 200 million people worldwide and results in persistent infection of approximately 80% of cases. Consequently, HCV is a leading… (more)

▼ Hepatitis C virus (HCV) infects over 200 million people worldwide and results in persistent infection of approximately 80% of cases. Consequently, HCV is a leading global contributor to severe liver disease. Although, direct-acting antiviral agents (DAA) are available, these drugs do not prevent re-infection and cost in excess of US $80, 000 per patient. Thus, the development of an inexpensive HCV vaccine represents the most effective measure to reduce the current epidemic. Patients who recover following acute HCV infections provide valuable clues for vaccine design. These patients develop a broad and sustained cell-mediated immunity (CMI) against multiple HCV proteins, in particular the non-structural (NS) proteins. Therefore, the focus of this thesis was to develop novel vaccine strategies to elicit CMI against HCV NS proteins which may mimic the immunity that facilitates spontaneous control of acute HCV infection. Dendritic cells (DC) are crucial to initiate CMI making these cells attractive targets for any vaccine. Recombinant porcine adenoviruses (rPAV) appear capable of targeting DC as rPAV encoding influenza virus antigens have been shown to elicit both humoral and CMI. Furthermore, rPAV are not infectious nor replicate in humans making them safe. The potential of rPAV to elicit HCV-specific CMI is unknown. Therefore, I attempted to construct a cytolytic rPAV encoding a lytic protein as the cytolytic nature of viruses significantly augments immunogenicity due to the release of natural adjuvants known as danger associated molecular patters (DAMPs) from infected cells. As a prelude to this aim, the lytic activity of two cytolytic proteins, namely adenovirus death protein (ADP) from AD5 and mouse perforin (PRF) were compared following transfection of HEK293T cells with pVAX DNA encoding ADP or PRF (chapter 3). In two independent cell death assays (viz. luciferase assay and lactate dehydrogenase release assay), it was determined that PRF was more lytic, making it a suitable protein to be encoded in a lytic rPAV HCV vaccine. I then attempted to modify the rPAV shuttle DNA to facilitate cloning and expression of HCV NS antigens. Initially, the efficiency of the truncated CMV (tCMV) promoter and the full-length CMV (fCMV) promoter to drive eGFP expression was compared. Using flow cytometry and confocal microscopy, the tCMV promoter was shown to be more efficient. In addition, the rPAV shuttle DNA was modified to contain a multiple cloning site to facilitate gene insertion. Subsequently, recombinant PAV plasmids encoding PRF controlled by the tCMV or SV40 promoters were constructed, but recombinant virus was not recovered. This is most likely because PRF killed the cells prior to virus assembly. Subsequently, several experiments were conducted (Chapter 5) with a reporter virus encoding LUC and eGFP and established that rPAV production requires early passage cells (P11) cultured for 10-14 days post transfection. Based on these results, a non-lytic rPAV devoid of PRF was constructed to elicit CMI to conserved HCV NS… Advisors/Committee Members: Gowans, Eric James (advisor), Wijesundara, Danushka (advisor), Grubor-Bauk, Branka (advisor), School of Medicine (school).

Subjects/Keywords: Hepatitis C; adenovirus; vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Jagdale, H. (2016). Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus. (Thesis). University of Adelaide. Retrieved from http://hdl.handle.net/2440/112856

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Jagdale, Harshwardhan. “Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus.” 2016. Thesis, University of Adelaide. Accessed February 25, 2020. http://hdl.handle.net/2440/112856.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Jagdale, Harshwardhan. “Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus.” 2016. Web. 25 Feb 2020.

Vancouver:

Jagdale H. Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus. [Internet] [Thesis]. University of Adelaide; 2016. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/2440/112856.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Jagdale H. Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus. [Thesis]. University of Adelaide; 2016. Available from: http://hdl.handle.net/2440/112856

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Debrecen

13. Nandul Durfa, Damcit. Hepatitis c and Treatment .

Degree: DE – Általános Orvostudományi Kar, University of Debrecen

URL: http://hdl.handle.net/2437/230508

► ABSTRACT Hepatitis C is a global epidemic that affects over 150 million people. The global prevalence of HCV infection is approximately 2.2 - 3% of… (more)

Subjects/Keywords: hepatitis c

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Nandul Durfa, D. (n.d.). Hepatitis c and Treatment . (Thesis). University of Debrecen. Retrieved from http://hdl.handle.net/2437/230508

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Nandul Durfa, Damcit. “Hepatitis c and Treatment .” Thesis, University of Debrecen. Accessed February 25, 2020. http://hdl.handle.net/2437/230508.

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Nandul Durfa, Damcit. “Hepatitis c and Treatment .” Web. 25 Feb 2020.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Nandul Durfa D. Hepatitis c and Treatment . [Internet] [Thesis]. University of Debrecen; [cited 2020 Feb 25]. Available from: http://hdl.handle.net/2437/230508.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

Council of Science Editors:

Nandul Durfa D. Hepatitis c and Treatment . [Thesis]. University of Debrecen; Available from: http://hdl.handle.net/2437/230508

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

Queen Mary, University of London

14. Cunningham, Morven Elizabeth. Developing new models to predict treatment outcome in patients with chronic hepatitis C infection.

Degree: PhD, 2016, Queen Mary, University of London

URL: http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775196

► Chronic infection with hepatitis C virus (HCV) is a significant global health problem, with approximately 170 million individuals infected worldwide. Treatment is rapidly evolving to… (more)

▼ Chronic infection with hepatitis C virus (HCV) is a significant global health problem, with approximately 170 million individuals infected worldwide. Treatment is rapidly evolving to combinations of highly potent direct-acting antiviral drugs, although optimal combinations for individual patient groups are not yet clear. Treatment failure still occurs, and relapse may occur in as many as 10% of treated individuals. Whilst HCV replicates primarily in the liver, HCV RNA has been identified in extrahepatic sites, including monocytes, although extrahepatic replication is controversial. Our group recently developed a novel assay to study replication of patient-derived HCV by fusion of patient monocytes with cultured hepatoma cells. In this study, we extended the utility of this fusion model, by using cell culture monocytes to 'capture' HCV from patient serum prior to fusion with hepatoma cells. We studied whether this 'capture-fusion' model could be used to screen individual patient drug response and the mechanisms permitting viral replication in the hybrid cells. Using the capture-fusion assay, patient-derived HCV of all viral genotypes replicated to levels detectable by a sensitive PCR assay and could be inhibited by antiviral drugs in a genotype-specific manner. Isolates with genotypic and phenotypic drug resistance could be identified, and, in a blinded study, drug sensitivity in the assay correlated with clinical treatment response. Relapse after interferon and ribavirin treatment was associated with poor pre-treatment ribavirin sensitivity and also with viable HCV in patient-derived monocytes at the end of therapy. Uptake of HCV into monocytes appeared independent of classical HCV entry receptors, and our work implicated CD64 in HCV monocyte entry. Cell fusion appeared to permit transfer of HCV RNA to hepatocytes without triggering an intracellular antiviral innate immune response. Our data suggest that this novel 'capture-fusion' model represents a promising new technique which may help identify appropriate treatment strategies for patients with chronic HCV infection.

Subjects/Keywords: Hepatitis C; capture-fusion assay

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Cunningham, M. E. (2016). Developing new models to predict treatment outcome in patients with chronic hepatitis C infection. (Doctoral Dissertation). Queen Mary, University of London. Retrieved from http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775196

Chicago Manual of Style (16^th Edition):

Cunningham, Morven Elizabeth. “Developing new models to predict treatment outcome in patients with chronic hepatitis C infection.” 2016. Doctoral Dissertation, Queen Mary, University of London. Accessed February 25, 2020. http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775196.

MLA Handbook (7^th Edition):

Cunningham, Morven Elizabeth. “Developing new models to predict treatment outcome in patients with chronic hepatitis C infection.” 2016. Web. 25 Feb 2020.

Vancouver:

Cunningham ME. Developing new models to predict treatment outcome in patients with chronic hepatitis C infection. [Internet] [Doctoral dissertation]. Queen Mary, University of London; 2016. [cited 2020 Feb 25]. Available from: http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775196.

Council of Science Editors:

Cunningham ME. Developing new models to predict treatment outcome in patients with chronic hepatitis C infection. [Doctoral Dissertation]. Queen Mary, University of London; 2016. Available from: http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775196

Kwame Nkrumah University of Science and Technology

15. Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako, Babatunde L. Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention.

Degree: 2014, Kwame Nkrumah University of Science and Technology

URL: http://dspace.knust.edu.gh:8080/jspui/handle/123456789/11854

►

The hepatitis C virus (HCV), which was not recognized as an infectious agent until the 1980s, is responsible for a worldwide epidemic. The World Health… (more)

Subjects/Keywords: Africa; epidemiology; hepatitis C; transmission.

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako, B. L. (2014). Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention. (Thesis). Kwame Nkrumah University of Science and Technology. Retrieved from http://dspace.knust.edu.gh:8080/jspui/handle/123456789/11854

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako, Babatunde L. “Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention.” 2014. Thesis, Kwame Nkrumah University of Science and Technology. Accessed February 25, 2020. http://dspace.knust.edu.gh:8080/jspui/handle/123456789/11854.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako, Babatunde L. “Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention.” 2014. Web. 25 Feb 2020.

Vancouver:

Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako BL. Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention. [Internet] [Thesis]. Kwame Nkrumah University of Science and Technology; 2014. [cited 2020 Feb 25]. Available from: http://dspace.knust.edu.gh:8080/jspui/handle/123456789/11854.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako BL. Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention. [Thesis]. Kwame Nkrumah University of Science and Technology; 2014. Available from: http://dspace.knust.edu.gh:8080/jspui/handle/123456789/11854

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of New South Wales

16. Yan, Kenneth Kar-Lung. Effects of ethnicity and metabolic factors on treatment responses and liver injury in chronic hepatitis C.

Degree: Clinical School - St George Hospital, 2010, University of New South Wales

URL: http://handle.unsw.edu.au/1959.4/45544 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:8841/SOURCE02?view=true

► Chronic hepatitis C affects more than 170 million people worldwide and is one of the most common infectious diseases on earth. If untreated, it can… (more)

▼ Chronic hepatitis C affects more than 170 million people worldwide and is one of the most common infectious diseases on earth. If untreated, it can lead to progressive liver injury, cirrhosis, liver failure and hepatocellular carcinoma. While curative antiviral therapy is currently available, it is far from 100% effective. The broad aim of this thesis is to examine factors influencing treatment response and liver injury in chronic hepatitis C virus.The first two studies examine treatment responses in ethnic groups where chronic hepatitis C is prevalent. A case-control study was conducted to compare the treatment responses between Arabic patients infected with genotype 4 with Caucasians infected with genotype 1 who were treated with interferon and ribavirin combination antiviral therapy, and found a superior sustained virological response rate of 64.0% , compared to that of 32.3% of genotype 1 infected patients, independent of other factors. Another retrospective case control study found Asians infected with chronic hepatitis C genotype 1 also had better sustained virological response rate of 73%, as compared to that of 36% of Caucasians infected with genotype 1. Findings of these two studies challenges the current clinical practice of extrapolating data from clinical trials originating from genotype 1 infected Caucasians, and treating different ethnic groups with same regimen, and prompted further research into treatment of different patient groups. The third study examined the role of two adipocytokines, namely adiponectin and retinal binding protein 4 in the pathogenesis of chronic hepatitis C by examining their serum levels and their expression at the genetic level in the liver, and contrasted that with non-alcoholic fatty liver disease. The study found that the relationship between insulin resistance and liver injury in chronic hepatitis C is probably independent from the effects of retinal binding protein 4. In addition, this study found the complex role of retinal binding protein 4 in non-alcoholic fatty liver disease, and prompted further research into identifying the pathways of adipocytokines in pathogenesis of chronic hepatitis C and non-alcoholic fatty liver disease. Advisors/Committee Members: Zekry, Amany, Clinical School - St George Hospital, Faculty of Medicine, UNSW, Grimm, Michael, Clinical School - St George Hospital, Faculty of Medicine, UNSW.

Subjects/Keywords: Treatment; Chronic hepatitis C; Ethnicity

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Yan, K. K. (2010). Effects of ethnicity and metabolic factors on treatment responses and liver injury in chronic hepatitis C. (Masters Thesis). University of New South Wales. Retrieved from http://handle.unsw.edu.au/1959.4/45544 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:8841/SOURCE02?view=true

Chicago Manual of Style (16^th Edition):

Yan, Kenneth Kar-Lung. “Effects of ethnicity and metabolic factors on treatment responses and liver injury in chronic hepatitis C.” 2010. Masters Thesis, University of New South Wales. Accessed February 25, 2020. http://handle.unsw.edu.au/1959.4/45544 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:8841/SOURCE02?view=true.

MLA Handbook (7^th Edition):

Yan, Kenneth Kar-Lung. “Effects of ethnicity and metabolic factors on treatment responses and liver injury in chronic hepatitis C.” 2010. Web. 25 Feb 2020.

Vancouver:

Yan KK. Effects of ethnicity and metabolic factors on treatment responses and liver injury in chronic hepatitis C. [Internet] [Masters thesis]. University of New South Wales; 2010. [cited 2020 Feb 25]. Available from: http://handle.unsw.edu.au/1959.4/45544 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:8841/SOURCE02?view=true.

Council of Science Editors:

Yan KK. Effects of ethnicity and metabolic factors on treatment responses and liver injury in chronic hepatitis C. [Masters Thesis]. University of New South Wales; 2010. Available from: http://handle.unsw.edu.au/1959.4/45544 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:8841/SOURCE02?view=true

University of New South Wales

17. Martinello, Marianne. Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy.

Degree: Kirby Institute, 2017, University of New South Wales

URL: http://handle.unsw.edu.au/1959.4/57843 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:45003/SOURCE02?view=true

► Background: The management of recent hepatitis C virus (HCV) infection is uncertain, as the therapeutic landscape evolves with the advent of direct-acting antiviral (DAA) therapy.Aims:… (more)

▼ Background: The management of recent hepatitis C virus (HCV) infection is uncertain, as the therapeutic landscape evolves with the advent of direct-acting antiviral (DAA) therapy.Aims: The broad aim of this research was to examine novel therapeutic strategies in recent HCV following the availability of DAA therapy. Specific aims included assessing the feasibility, efficacy and safety of response-guided interferon (IFN)-containing and ultra-short IFN-free therapy; calculating reinfection incidence following treatment; and determining the clinical significance of drug-drug interactions in HIV/HCV co-infection.Methods: In Chapters Two and Three, the efficacy and safety of short and/or response-guided treatment among individuals with recent HCV was examined in three open-label trials: ATAHC II (n=52; pegylated-IFN +/- ribavirin), DARE-C I (n=14; pegylated-IFN, ribavirin + telaprevir) and DARE-C II (n=19; sofosbuvir + ribavirin). In Chapter Four, reinfection incidence following treatment for recent HCV was calculated among those who achieved an end-of-treatment response in ATAHC I and II, DARE-C I and II (n=120). In Chapter Five, a simulation of potential drug-drug interactions between combination antiretroviral therapy and DAAs was performed in those with HIV/HCV enrolled in CEASE-D (n=257).Key Findings: A total of 85 individuals (73% HIV) with recent HCV commenced short and/or response-guided treatment between 2010 and 2015; none of the strategies trialled was optimal. Given toxicity, the applicability of an IFN-containing strategy is limited. Conversely, six weeks of sofosbuvir and ribavirin was safe and well tolerated, but efficacy was poor. High reinfection incidence, particularly in individuals reporting injection drug use following treatment, was seen. These trials confirmed the feasibility of short duration therapy in recent HCV and informed contemporary trial design. Optimal DAA regimen choice for future research will be crucial; the combination of a nucleotide analogue and an NS5A inhibitor appears appropriate given potency and little potential for drug-drug interactions in HIV/HCV co-infection.Conclusion: The role and efficacy of ultra-short duration therapy in recent HCV requires further evaluation with potent DAA regimens. The significant risk for HCV reinfection following treatment in individuals with ongoing behaviour facilitating transmission emphasises the need for post-treatment surveillance, harm reduction strategies and education. Advisors/Committee Members: Matthews, Gail, Kirby Institute, Faculty of Medicine, UNSW, Dore, Gregory, Kirby Institute, Faculty of Medicine, UNSW.

Subjects/Keywords: Treatment; Hepatitis C; Acute

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Martinello, M. (2017). Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy. (Doctoral Dissertation). University of New South Wales. Retrieved from http://handle.unsw.edu.au/1959.4/57843 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:45003/SOURCE02?view=true

Chicago Manual of Style (16^th Edition):

Martinello, Marianne. “Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy.” 2017. Doctoral Dissertation, University of New South Wales. Accessed February 25, 2020. http://handle.unsw.edu.au/1959.4/57843 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:45003/SOURCE02?view=true.

MLA Handbook (7^th Edition):

Martinello, Marianne. “Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy.” 2017. Web. 25 Feb 2020.

Vancouver:

Martinello M. Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy. [Internet] [Doctoral dissertation]. University of New South Wales; 2017. [cited 2020 Feb 25]. Available from: http://handle.unsw.edu.au/1959.4/57843 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:45003/SOURCE02?view=true.

Council of Science Editors:

Martinello M. Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy. [Doctoral Dissertation]. University of New South Wales; 2017. Available from: http://handle.unsw.edu.au/1959.4/57843 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:45003/SOURCE02?view=true

Rutgers University

18. Wang, Yuanyuan, 1991-. Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system.

Degree: PhD, Chemistry and Chemical Biology, 2019, Rutgers University

URL: https://rucore.libraries.rutgers.edu/rutgers-lib/60087/

►

Hepatitis C is a liver disease caused by hepatitis C virus (HCV). HCV is the major cause of cirrhosis and hepatocellular cancer in the US… (more)

▼

Hepatitis C is a liver disease caused by hepatitis C virus (HCV). HCV is the major cause of cirrhosis and hepatocellular cancer in the US and is the number one cause of liver transplantation. An estimate of 3.5 million people is chronically infected in the US with 400,000 individuals deaths from chronic HCV infection every year. Several direct-acting antiviral (DAA) agents have been approved by the Food and Drug Administration (FDA). HCV is a blood-borne virus, which prior to 1992 was transmitted through blood transfusion. An estimated 41,200 new cases of HCV infection occurred in the US with an additional 1.75 million worldwide in 2016. Therefore, there is an urgent need to control the transmission of HCV, in addition to the antiviral intervention to limit the spread of the virus. Vaccination is the most effective way to control the infection rate as no infectious disease has ever been eradicated by treatment alone. However, no vaccine is available to prevent HCV infection. A useful mammalian cell expression system was described to produce HCV envelope glycoproteins E1 and E2, as well as the cell surface receptors, scavenger receptor class B type I (SRB1) and cluster of differentiation 81 (CD81). Our method combines the speed and high efficiency of lentiviral infection with an adherent cell bioreactor to allow large-scale production of proteins in mammalian cell lines. The full-length ectodomain of HCV E1 was produced at milligram quantity and is recognized by conformational antibodies from patient samples. E1 can associate with the apolipoproteins from the cell culture serum. HCV E2 produced by the mammalian cell expression system has the function to bind cell surface receptors and antibodies. Crystals of E2 and CD81 diffract to 4.3 Å resolution allowing us to produce a low-resolution model of the E2-receptor complex. Overall, our result extends the current understanding of HCV entry by providing more structural, biophysical, and functional information on the HCV glycoproteins. The studies of the receptor interaction can contribute to vaccine design to halt the spread of HCV infection.

Advisors/Committee Members: Marcotrigiano, Joseph (chair), Case, David (internal member), Baum, Jean (internal member), Arnold, Eddy (internal member), Cohen, Jeffrey (outside member), School of Graduate Studies.

Subjects/Keywords: Hepatitis C virus – Treatment

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Wang, Yuanyuan, 1. (2019). Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system. (Doctoral Dissertation). Rutgers University. Retrieved from https://rucore.libraries.rutgers.edu/rutgers-lib/60087/

Chicago Manual of Style (16^th Edition):

Wang, Yuanyuan, 1991-. “Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system.” 2019. Doctoral Dissertation, Rutgers University. Accessed February 25, 2020. https://rucore.libraries.rutgers.edu/rutgers-lib/60087/.

MLA Handbook (7^th Edition):

Wang, Yuanyuan, 1991-. “Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system.” 2019. Web. 25 Feb 2020.

Vancouver:

Wang, Yuanyuan 1. Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system. [Internet] [Doctoral dissertation]. Rutgers University; 2019. [cited 2020 Feb 25]. Available from: https://rucore.libraries.rutgers.edu/rutgers-lib/60087/.

Council of Science Editors:

Wang, Yuanyuan 1. Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system. [Doctoral Dissertation]. Rutgers University; 2019. Available from: https://rucore.libraries.rutgers.edu/rutgers-lib/60087/

19. Calland, Noémie. L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry.

Degree: Docteur es, Biochimie et biologie moléculaire, 2012, Université Lille II – Droit et Santé

URL: http://www.theses.fr/2012LIL2S031

► L’hépatite C est un problème majeur de santé publique qui touche environ 160 millions de personnes dans le monde. L’agent étiologique responsable de cette maladie,… (more)

▼ L’hépatite C est un problème majeur de santé publique qui touche environ 160 millions de personnes dans le monde. L’agent étiologique responsable de cette maladie, le virus de l’hépatite C (HCV), est un petit virus enveloppé dont le génome est codé par un acide ribonucléique (ARN) simple brin de polarité positive. Actuellement, il n’existe aucun vaccin contre ce pathogène et les traitements utilisés sont insatisfaisants du fait de leur spécificité d’action limitée. Ainsi, afin d’établir une thérapie antivirale efficace évitant l’apparition et la sélection de mutants de résistance aux antiviraux, l’utilisation de plusieurs agents antiviraux ciblant directement la particule virale (direct acting antiviral agents ou DAAs) en combinaison est préconisée. C’est pourquoi la découverte de nouveaux DAAs à large spectre d’action ciblant diverses étapes du cycle viral infectieux est indispensable.Au cours de ma thèse, nous avons identifié un nouvel inhibiteur de l’entrée du HCV : l’épigallocatéchine-3-gallate (EGCG). Cette molécule, extraite du thé vert, inhibe l’infection des cellules par le HCV. Plus précisément, en utilisant des particules rétrovirales pseudotypées avec les glycoprotéines d’enveloppe E1 et E2 du HCV, nous avons démontré que cette catéchine naturelle, agit à une étape très précoce de l’entrée virale, indépendamment du génotype. De même, en nous servant du virus produit en culture cellulaire, nous avons montré que cette molécule agit directement sur la particule virale. Puis, par RT-PCR quantitative (quantitative real-time polymerase chain reaction), nous avons confirmé l’inhibition de la liaison du virus à la surface cellulaire, en présence d’EGCG. Par conséquent, nos travaux suggèrent que l’EGCG interagit avec la particule virale, probablement en se liant aux glycoprotéines d’enveloppe virales, bloquant ainsi une étape initiale d’attachement entre le virus et les facteurs cellulaires présents à la surface de l’hépatocyte. Puis, en inhibant la transmission libre du virus, à l’aide, soit d’agarose, soit d’anticorps neutralisants, nous avons démontré que l’EGCG inhibe la transmission du virus de cellule à cellule. Enfin, nous avons montré que l’EGCG élimine le virus présent dans le surnageant de culture cellulaire après quatre passages successifs sur des cellules naïves.La concentration d’EGCG nécessaire pour inhiber la moitié de l’infection virale (IC50) en culture cellulaire est 11 µM. Ainsi, afin d’identifier de nouvelles molécules présentant un mode d’action similaire à celui de l’EGCG et possédant une meilleure activité antivirale, nous avons sélectionnés différentes molécules naturelles et les avons testés pour leur potentiel effet anti-HCV. C’est ainsi que le chlorure de delphinidine, une anthocyanidine, a également été identifié en tant que nouvelle molécule inhibitrice de l’entrée du HCV. De même que l’EGCG, le chlorure de delphinidine cible directement la particule virale à une étape précoce de l’entrée, indépendamment du génotype, probablement en inhibant l’attachement du virus à la surface… Advisors/Committee Members: Séron, Karin (thesis director).

Subjects/Keywords: EGCG; Delphinidine; Hépatite C; Hepatitis C virus

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Calland, N. (2012). L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry. (Doctoral Dissertation). Université Lille II – Droit et Santé. Retrieved from http://www.theses.fr/2012LIL2S031

Chicago Manual of Style (16^th Edition):

Calland, Noémie. “L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry.” 2012. Doctoral Dissertation, Université Lille II – Droit et Santé. Accessed February 25, 2020. http://www.theses.fr/2012LIL2S031.

MLA Handbook (7^th Edition):

Calland, Noémie. “L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry.” 2012. Web. 25 Feb 2020.

Vancouver:

Calland N. L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry. [Internet] [Doctoral dissertation]. Université Lille II – Droit et Santé 2012. [cited 2020 Feb 25]. Available from: http://www.theses.fr/2012LIL2S031.

Council of Science Editors:

Calland N. L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry. [Doctoral Dissertation]. Université Lille II – Droit et Santé 2012. Available from: http://www.theses.fr/2012LIL2S031

Universidade Federal de Mato Grosso do Sul

20. Tetila, Andyane Freitas. Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C .

Degree: 2011, Universidade Federal de Mato Grosso do Sul

URL: http://repositorio.cbc.ufms.br:8080/jspui/handle/123456789/1847

► A infecção pelo vírus da hepatite C (HCV) não é rara em indivíduos infectados pelo vírus da imunodeficiência humana (HIV) e representa um importante problema… (more)

Subjects/Keywords: HIV; Coinfecção; Coinfection; Hepatite C; Hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Tetila, A. F. (2011). Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C . (Thesis). Universidade Federal de Mato Grosso do Sul. Retrieved from http://repositorio.cbc.ufms.br:8080/jspui/handle/123456789/1847

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Tetila, Andyane Freitas. “Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C .” 2011. Thesis, Universidade Federal de Mato Grosso do Sul. Accessed February 25, 2020. http://repositorio.cbc.ufms.br:8080/jspui/handle/123456789/1847.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Tetila, Andyane Freitas. “Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C .” 2011. Web. 25 Feb 2020.

Vancouver:

Tetila AF. Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C . [Internet] [Thesis]. Universidade Federal de Mato Grosso do Sul; 2011. [cited 2020 Feb 25]. Available from: http://repositorio.cbc.ufms.br:8080/jspui/handle/123456789/1847.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Tetila AF. Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C . [Thesis]. Universidade Federal de Mato Grosso do Sul; 2011. Available from: http://repositorio.cbc.ufms.br:8080/jspui/handle/123456789/1847

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

21. Karamichali, Eirini. Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C.

Degree: 2014, University of Patras; Πανεπιστήμιο Πατρών

URL: http://hdl.handle.net/10442/hedi/35595

►

HCV infection is a major public health problem and a leading cause of chronic liver disease and hepatocellular carcinoma, with approximately 180 million infected individuals… (more)

▼

HCV infection is a major public health problem and a leading cause of chronic liver disease and hepatocellular carcinoma, with approximately 180 million infected individuals worldwide. HCV is a positive sense RNA virus that belongs to the genus hepacivirus of the Flaviviridae family. Six major HCV genotypes (1–6) are known, each of which can be further subdivided into several subtypes (1a, 1b, 2a, etc). The HCV genome consists of a large open reading frame (ORF), flanked by highly structured 5’ and 3’ untranslated regions (UTRs). Both UTRs are conserved and control viral translation and replication. The HCV 5'-UTR contains an IRES that initiates cap-independent translation of the viral RNA. IRES-mediated translation of the HCV ORF yields a single polyprotein precursor that is co- and post-translationally processed by cellular and viral proteases, giving rise to mature structural and non structural proteins. Several studies have suggested that different cellular non canonical proteins or viral proteins can regulate the HCV IRES activity. The aim of this study was to understand the regulation of the HCV IRES dependent translation. Firstly, we tried to delineate the role of the viral proteins on HCV IRES dependent translation that still remains controversial. Clearly our studies demonstrated that HCV NS5A down-regulates IRES activity in a cell-type dependent manner. Additionally, we provide strong evidence that activated PKR up-regulates the IRES activity while silencing of endogenous PKR had the opposite effect. In addition, we concluded that the NS5A-mediated inhibitory effect on IRES-dependent translation was linked with the PKR inactivation. Moreover, as it is already reported that localised hypoxic areas are continuously present in HCC due to its high proliferation rate leading to an altered translation pattern, we investigated modulation of HCV IRES activity under low oxygen settings. Our results provided preliminary evidence that HCV-IRES-dependent translation is negatively regulated by low oxygen levels or under hypoxia-mimicking conditions in cell-specific manner.

H λοίμωξη που προκαλείται απο τον ιό της ηπατίτιδας C HCV είναι μείζον πρόβλημα για την δημόσια υγεία όπως επίσης και η κύρια αιτία της χρόνιας ηπατικής νόσου και ηπατοκυτταρικού καρκινώματος, με περίπου 180 εκατομμύρια μολυσμένα άτομα σε όλο τον κόσμο. Ο HCV είναι ένας RNA ιός θετικής πολικότητας που ανήκει στο γένος Hepacivirus της οικογένειας των Flaviviridae. Έξι γονότυποι ( 1-6 ) είναι γνωστοί, καθένας από τους οποίους μπορεί να υποδιαιρεθεί περαιτέρω σε αρκετές υποτύπους. Το γονιδίωμα του HCV αποτελείται από ένα μεγάλο ανοικτό πλαίσιο ανάγνωσης (ORF), πλαισιωμένο από ιδιαίτερα δομημένες 5 'και 3' αμετάφραστες περιοχές (UTRs). Και οι δύο περιοχές UTRs είναι συντηρημένες και έχουν τον έλεγχο της ιογενούς μετάφρασης και αναπαραγωγής. Το 5' UTR του HCV περιέχει μια περιοχή IRES απο την οποία γινεται η έναρξη της cap ανεξάρτητης μετάφρασης του ιικού RNA. Η HCV IRES εξαρτώμενη μετάφραση του ORF παράγει μια ενιαία πρόδρομη…

Subjects/Keywords: Ηπατίτιδα C, Ιός (HCV); Hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Karamichali, E. (2014). Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C. (Thesis). University of Patras; Πανεπιστήμιο Πατρών. Retrieved from http://hdl.handle.net/10442/hedi/35595

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Karamichali, Eirini. “Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C.” 2014. Thesis, University of Patras; Πανεπιστήμιο Πατρών. Accessed February 25, 2020. http://hdl.handle.net/10442/hedi/35595.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Karamichali, Eirini. “Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C.” 2014. Web. 25 Feb 2020.

Vancouver:

Karamichali E. Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C. [Internet] [Thesis]. University of Patras; Πανεπιστήμιο Πατρών; 2014. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/10442/hedi/35595.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Karamichali E. Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C. [Thesis]. University of Patras; Πανεπιστήμιο Πατρών; 2014. Available from: http://hdl.handle.net/10442/hedi/35595

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

22. Polydoros, Konstantinides. Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D.

Degree: 2019, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)

URL: http://hdl.handle.net/10442/hedi/46058

►

Several studies have provided conflicting results regarding the immune responses in chronic hepatitis C (CHC) patients with mixed cryoglobulinemia (MC). The importance of B-cell activating… (more)

▼

Several studies have provided conflicting results regarding the immune responses in chronic hepatitis C (CHC) patients with mixed cryoglobulinemia (MC). The importance of B-cell activating factor (BAFF) in MC has been described, but the role of interleukin (IL)-17A is less clear. Aim of the Study: The main objectives were to determine the levels of BAFF and IL-17A cytokines in patients with CHC with or without MC, and to investigate their kinetics during antiviral treatment with pegylated interferon-α/ribavirin and 6 months after the end of it. In addition, the aim was to evaluate the possible correlation of cytokines with vitD levels, the degree of hepatic fibrosis and the response to antiviral therapy. Furthermore, the results were correlated with demographic and laboratory data of the patients under study.Methods: Serum concentrations of IL-17A, BAFF and 25-OH vitamin D were measured in 34 CHC patients at baseline, end of treatment, and 6 months post-treatment with pegylated interferon-α and ribavirin, versus 12 healthy controls.Results: Thirty-four patients (20 male, mean age 40.7±9.2 years, 12 of genotype 1 or 4, 22 of genotype 2 or 3) were included, of whom 64.7% achieved a sustained virological response (SVR). MC was detected in 52.9% of the patients. Higher levels of both cytokines were found in patients with MC compared to those without. Patients who achieved SVR had higher pretreatment IL-17A and lower BAFF levels compared to those without SVR. IL-17A was downregulated during and following treatment in responders, whereas upregulation was observed in non-responders. CHC patients demonstrated low vitamin D levels compared to HC. Moreover, the changes in IL-17A over the treatment period were significantly associated with vitamin D changes (β=-0.04, SE=0.02, P=0.046). No difference in IL-17A, BAFF and vitamin D values was seen between patients with cirrhosis (n=14) and those without.Conclusions: CHC patients with asymptomatic MC have increased levels of IL-17A and BAFF. IL-17A levels decline significantly while BAFF increases during treatment in responders. An interplay between IL-17A and vitamin D concentrations was revealed during the antiviral treatment.Keywords: Interleukin 17A, B-cell activating factor, vitamin D, chronic hepatitis C, mixed cryoglobulinemia

Αρκετές μελέτες παρουσίασαν αντικρουόμενα αποτελέσματα σχετικά με τις ανοσολογικές αντιδράσεις σε ασθενείς με χρόνια ηπατίτιδα C (CHC) και μικτή κρυοσφαιριναιμία (MC). Η σημασία του ενεργοποιητικού παράγοντα των Β λεμφοκυττάρων (BAFF) στη MC έχει περιγραφεί προηγουμένως, αλλά ο ρόλος της ιντερλευκίνης (IL)-17A είναι λιγότερο σαφής. Σκοπός: Οι κύριοι στόχοι της παρούσας μελέτης ήταν ο προσδιορισμός των επιπέδων των κυτταροκινών BAFF και IL-17A σε ασθενείς που πάσχουν από CHC με ή χωρίς MC, και η διερεύνηση της κινητικής τους κατά τη διάρκεια της αντιιικής θεραπείας με pegIFN/RBV και 6 μήνες μετά το τέλος αυτής. Επιπρόσθετα, θέλαμε να αξιολογήσουμε τη σχέση των κυτταροκινών με τα επίπεδα της vitD, το βαθμό της ηπατικής ίνωσης και την ανταπόκριση στην…

Subjects/Keywords: Χρόνια ηπατίτιδα C; Chronic hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Polydoros, K. (2019). Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D. (Thesis). National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Retrieved from http://hdl.handle.net/10442/hedi/46058

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Polydoros, Konstantinides. “Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D.” 2019. Thesis, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Accessed February 25, 2020. http://hdl.handle.net/10442/hedi/46058.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Polydoros, Konstantinides. “Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D.” 2019. Web. 25 Feb 2020.

Vancouver:

Polydoros K. Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D. [Internet] [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2019. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/10442/hedi/46058.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Polydoros K. Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D. [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2019. Available from: http://hdl.handle.net/10442/hedi/46058

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

23. Kotsiri, Ioanna. Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα.

Degree: 2016, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)

URL: http://hdl.handle.net/10442/hedi/37543

►

Summary: TGF-β1 is an important pre-fibrinogenic cytokine, which is produced by the non-parenchymal liver cells, activates the hepatic asteroid cells and has been involved in… (more)

▼

Summary: TGF-β1 is an important pre-fibrinogenic cytokine, which is produced by the non-parenchymal liver cells, activates the hepatic asteroid cells and has been involved in the pathogenesis of liver fibrosis. For that reason, its role in the evolution of liver fibrosis has been studied for many years in patients with chronic hepatitis C (CHC) as well as with chronic hepatitis B. The purpose of this dissertation was to study the serum TGF-β1 levels, in association with liver fibrosis and to examine their change according to treatment response and their value as a predictive index in patients with CHC under antiviral treatment.Eighty four patients were included in the study (average age 46 years- old, 44 men, 40 women) with CHC belonging to all known HCV genotypes and were treated with pegylated interferon plus ribavirin. Liver fibrosis was estimated non-invasively with liver transient elastography. TGF-β1 levels were measured before and at the end of follow-up and 6 months after the completion of antiviral therapy using a standard immunoassay.TGF-β1 levels were not associated with epidemiological, biochemical or virological parameters. Univariate analysis showed association between antiviral treatment, age and white blood count, but not with the initial TGF-β1 levels. For patients with sustained virological response (SVR) TGF-β1 levels were significantly decreased at the end (12.327 pg/ml, p<0.0001) and 6 months after the completion of antiviral therapy (13.555 pg/ml, p=0.007) compared to baseline values (17.166 pg/ml), but not in patients showing relapse (11.487 vs 12.241 or 9.648 pg/ml, p=0.814 or p=0.344) or in patients showing non-response (16.319 vs 11.362 or 11.977 pg/ml, p=0.227 or p=0.695). There was no association between TGF-β1 and degree of liver fibrosis as estimated with transient elastography at baseline (p=0.29).In conclusion, our results shown that TGF-β1 displayed significant decrease in CHC patients with SVR to antiviral therapy. TGF-β1 levels are not associated with degree of liver fibrosis or to response to antiviral treatment.

ΠΕΡΙΛΗΨΗ: Ο TGF-β1 είναι μια σημαντική προ-ινωδογόνος κυτταροκίνη, παράγεται από τα μη παρεγχυματικά ηπατοκύτταρα, ενεργοποιεί τα ηπατικά αστεροειδή κύτταρα και έχει εμπλακεί στην παθογένεση της ηπατικής ίνωσης. Γι΄αυτό, ο ρόλος του στην εξέλιξη της ηπατικής ίνωσης έχει μελετηθεί για πολλά χρόνια, σε ασθενείς με χρόνια ηπατίτιδα C (CΗC) όσο και με χρόνια ηπατίτιδα B.Σκοπός της παρούσας διατριβής ήταν η μελέτη των επιπέδων του TGF-β1 στον ορό, η συσχέτισή τους με την ηπατική ίνωση, η μεταβολή τους ανάλογα με την ανταπόκριση στη θεραπεία, και η αξία του ως προγνωστικός δείκτης σε ασθενείς με χρόνια ηπατίτιδα C (CΗC) υπό αντιική θεραπεία.Στην μελέτη εντάχθηκαν 84 ασθενείς (μέση ηλικία 46 έτη, 44 άνδρες/40 γυναίκες) με ΧΗC όλων των γονοτύπων και τους χορηγήθηκε συνδυασμένη θεραπεία με πεγκυλιωμένη ιντερφερόνη και ριμπαβιρίνη. Η ηπατική ίνωση εκτιμήθηκε μη επεμβατικά με ελαστογραφία ήπατος. Τα επίπεδα του TGF-β1 στον ορό μετρήθηκαν πριν την έναρξη, στο τέλος και στους 6…

Subjects/Keywords: Χρόνια ηπατίτιδα C; Chronic hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Kotsiri, I. (2016). Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα. (Thesis). National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Retrieved from http://hdl.handle.net/10442/hedi/37543

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Kotsiri, Ioanna. “Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα.” 2016. Thesis, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Accessed February 25, 2020. http://hdl.handle.net/10442/hedi/37543.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Kotsiri, Ioanna. “Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα.” 2016. Web. 25 Feb 2020.

Vancouver:

Kotsiri I. Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα. [Internet] [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2016. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/10442/hedi/37543.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Kotsiri I. Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα. [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2016. Available from: http://hdl.handle.net/10442/hedi/37543

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Ryerson University

24. Zalai, Dora, Marta. Fatigue in chronic hepatitis C infection a mixed method study.

Degree: 2014, Ryerson University

URL: https://digital.library.ryerson.ca/islandora/object/RULA%3A2995

► Fatigue is a main patient reported outcome of chronic hepatitis C (HCV) infection; yet its contributors are unknown. Objectives: The study (1) evaluated fatigue predictors,… (more)

Subjects/Keywords: Hepatitis C.; Hepatitis C virus.; Fatigue; Sleep disorders

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Zalai, Dora, M. (2014). Fatigue in chronic hepatitis C infection a mixed method study. (Thesis). Ryerson University. Retrieved from https://digital.library.ryerson.ca/islandora/object/RULA%3A2995

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Zalai, Dora, Marta. “Fatigue in chronic hepatitis C infection a mixed method study.” 2014. Thesis, Ryerson University. Accessed February 25, 2020. https://digital.library.ryerson.ca/islandora/object/RULA%3A2995.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Zalai, Dora, Marta. “Fatigue in chronic hepatitis C infection a mixed method study.” 2014. Web. 25 Feb 2020.

Vancouver:

Zalai, Dora M. Fatigue in chronic hepatitis C infection a mixed method study. [Internet] [Thesis]. Ryerson University; 2014. [cited 2020 Feb 25]. Available from: https://digital.library.ryerson.ca/islandora/object/RULA%3A2995.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Zalai, Dora M. Fatigue in chronic hepatitis C infection a mixed method study. [Thesis]. Ryerson University; 2014. Available from: https://digital.library.ryerson.ca/islandora/object/RULA%3A2995

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of KwaZulu-Natal

25. Shunmugam, Letitia. In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase.

Degree: 2019, University of KwaZulu-Natal

URL: https://researchspace.ukzn.ac.za/handle/10413/16623

► Hepatitis C Virus (HCV) is an escalating global healthcare and economic burden that requires extensive intervention to alleviate its control. Over the years, drug design… (more)

▼ Hepatitis C Virus (HCV) is an escalating global healthcare and economic burden that requires extensive intervention to alleviate its control. Over the years, drug design efforts have produced many anti-HCV drugs; however, due to drug resistance brought on by numerous genetic variations of the virus and lack of specificity and stability, current drugs are rendered ineffective. The situation has been further intensified by the absence of a viable vaccine. For these reasons, continuous HCV research is imperative for the design and development of promising inhibitors that address the challenges faced by present antiviral therapies. Moreover, exposure of previously neglected viral protein targets can offer another potentially valuable therapeutic route in drug design research. Structure-based drug design approaches accentuate the development of small inhibitor molecules that interact with therapeutic targets through non-covalent interactions. The unexpected discovery of covalent inhibitors and their distinctive nature of instigating complete and irreversible inhibition of targets have shifted attention away from the use of non-covalent drugs in antiviral treatment. This has led to significant progress in understanding covalent inhibition regarding their underlying mechanism of action and in the design of novel covalent inhibitors that work against biological targets. However, due to difficulties arising in its application and resultant safety, the pharmaceutical industry were reluctant to pursue this strategy. With the use of rational drug design, a novel strategy was then proposed known as selective covalent inhibition. Due to the lack of competent protocols and information, little is known regarding selective covalent inhibition This study investigates three biological HCV targets, NS3 protease, RNA helicase and NS5B RNAdependent RNA polymerase. With constantly evolving viruses like HCV, computational methods including molecular modelling and docking, virtual screening and molecular dynamic simulations have allowed chemists to screen millions of compounds to filter out potential lead drugs. These in silico approaches have allowed Computer-Aided Drug Design as a cost-effective strategy to accelerate the process of drug discovery. The above techniques, with numerous other computational tools were employed in this study to fill the gap in HCV drug research by providing insights into the structural and dynamic changes that describe the mechanism of selective covalent inhibition and pharmacophoric features that lead to unearthing of potential small inhibitor molecules against Hepatitis C. v The first study (Chapter 4) provides a comprehensive review on HCV NS3/4A protein, current therapies and covalent inhibition as well as introduces a technical guideline that provides a systematic approach for the design and development of potent, selective HCV inhibitors. The second study (Chapter 5) provides a comprehensive understanding concerning the implications of selective covalent inhibition on the… Advisors/Committee Members: Soliman, Mahmoud E S. (advisor).

Subjects/Keywords: Hepatitis C virus - drug design.; Hepatitis C virus - drug delivery.

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Shunmugam, L. (2019). In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase. (Thesis). University of KwaZulu-Natal. Retrieved from https://researchspace.ukzn.ac.za/handle/10413/16623

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Shunmugam, Letitia. “In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase.” 2019. Thesis, University of KwaZulu-Natal. Accessed February 25, 2020. https://researchspace.ukzn.ac.za/handle/10413/16623.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Shunmugam, Letitia. “In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase.” 2019. Web. 25 Feb 2020.

Vancouver:

Shunmugam L. In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase. [Internet] [Thesis]. University of KwaZulu-Natal; 2019. [cited 2020 Feb 25]. Available from: https://researchspace.ukzn.ac.za/handle/10413/16623.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Shunmugam L. In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase. [Thesis]. University of KwaZulu-Natal; 2019. Available from: https://researchspace.ukzn.ac.za/handle/10413/16623

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

26. Villegas Chiroque, Miguel. Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011.

Degree: 2013, National University of San Marcos

URL: http://cybertesis.unmsm.edu.pe/handle/cybertesis/3409

►

Se realizó un estudio retrospectivo de casos y controles para evaluar los factores predictivos de eficacia del tratamiento combinado con interferón pegilado alfa (Peg IFN)… (more)

▼

Se realizó un estudio retrospectivo de casos y controles para evaluar los factores predictivos de eficacia del tratamiento combinado con interferón pegilado alfa (Peg IFN) y ribavirina (RBV) contra la hepatitis C crónica en un hospital de Lima Perú, años 2006-2011. Se incluyó 34 casos consecutivos de sujetos con Respuesta Virológica Sostenida (RVS) y 36 controles temporales sin RVS, entre quienes se determinó 16 variables epidemiológicas, clínicas y de tratamiento. Se utilizó el análisis univariado de regresión logística a través del programa estadístico Epi Info. Los hallazgos fueron: ninguno de los factores epidemiológicos, como edad, género, procedencia e ingesta alcohólica se relacionó con la RVS; de los factores clínicos evaluados, como: IMC, score Child-Pugh, índice MELD, transaminasemia y grado de fibrosis, solo el estadío Child A (OR=9,45; p<0,05) se relacionó con RVS; y de los factores de tratamiento, la carga viral ≤ 600 mil UI/mL (OR=2,68; p<0,05), la Respuesta Virológica Rápida (RVR; OR=58,4; p<0,01), y la Respuesta Virológica Precoz (RVP; OR=14,5; p<0,05) se asociaron con la RVS. En conclusión, los factores predictores de la RVS en los pacientes con terapia para VHC fueron: la enfermedad hepática compensada (Child-Pugh A), la RVP, y sobretodo, la RVR. Palabras Claves: Hepatitis C crónica (HCC), Virus de hepatitis C (VHC), Respuesta Virológica Sostenida (RVS).

– We performed a retrospective study of cases and controls to assess predictors of efficacy of combination therapy with pegylated interferon alpha (Peg IFN-) and ribavirin (RBV) for hepatitis C infection in a hospital in Lima Peru, years 2006 2011. It included 34 consecutive cases of patients with Sustained Virological Response (SVR) and 36 controls without SVR, among whom was determined 16 variables epidemiological, clinical and treatment. We used univariate logistic regression analysis through statistical program Epi Info. The findings were: none of the epidemiological factors such as age, gender, origin and alcohol intake, were associated with SVR; clinical factors evaluated, as: BMI, Child-Pugh score, MELD index, transaminasemia and degree of fibrosis; only stage Child A (OR = 9,45; p <0.05) was associated with SVR, and treatment factors, the load viral ≤ 600 000 IU/mL (OR = 2,68; p <0.05), Rapid Virological Response (RVR; OR = 58.4; p <0.01), and Early Virological Response (EVR; OR = 14,5 ; p <0.05) were associated with SVR. In conclusion, predictors of SVR in patients with HCV therapy were: the compensated liver disease (Child-Pugh A), the RVP, and above all, the RVR. Keywords: Hepatitis C Chronic (HCC), Hepatitis C Virus (HCV), Sustained Virological Response (SVR).

Subjects/Keywords: Hepatitis C - Tratamiento; Virus de la hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Villegas Chiroque, M. (2013). Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011. (Thesis). National University of San Marcos. Retrieved from http://cybertesis.unmsm.edu.pe/handle/cybertesis/3409

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Villegas Chiroque, Miguel. “Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011.” 2013. Thesis, National University of San Marcos. Accessed February 25, 2020. http://cybertesis.unmsm.edu.pe/handle/cybertesis/3409.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Villegas Chiroque, Miguel. “Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011.” 2013. Web. 25 Feb 2020.

Vancouver:

Villegas Chiroque M. Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011. [Internet] [Thesis]. National University of San Marcos; 2013. [cited 2020 Feb 25]. Available from: http://cybertesis.unmsm.edu.pe/handle/cybertesis/3409.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Villegas Chiroque M. Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011. [Thesis]. National University of San Marcos; 2013. Available from: http://cybertesis.unmsm.edu.pe/handle/cybertesis/3409

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Indian Institute of Science

27. Bose, Mihika. Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors.

Degree: 2016, Indian Institute of Science

URL: http://etd.iisc.ernet.in/handle/2005/2920 ; http://etd.ncsi.iisc.ernet.in/abstracts/3782/G27861-Abs.pdf

► Hepatitis C virus (HCV) represents a global health threat. HCV is a blood-borne positive-strand RNA virus belonging to the Flaviviridae family that infects ~160 million… (more)

▼ Hepatitis C virus (HCV) represents a global health threat. HCV is a blood-borne positive-strand RNA virus belonging to the Flaviviridae family that infects ~160 million people worldwide. About 70% of infected individuals fail to clear the virus and subsequently develop chronic hepatitis, frequently leading to liver cirrhosis and in some cases hepatocellular carcinoma. Therapeutic options for HCV infection are still limited and a protective vaccine is not yet available. Currently available therapies include administration of pegylated alpha interferon in combination with ribavirin. The recently approved protease inhibitors Boceprevir and Telaprevir are also included in the treatment regimen. However, limitations to the treatment with direct-acting antivirals (DAAs) are associated with severe side effects and low sustained virological response (SVR) rates that vary depending on the virus and host genotype. The replication step of the viral life cycle is mostly targeted by majority of DAAs. Recent findings have suggested that a combination of entry inhibitors together with DAAs exhibit a synergistic effect in the treatment of HCV. Therefore, identification of efficient HCV entry inhibitors is of high priority In vitro studies have shown that HCV attachment and subsequent entry into the host cells is mediated by E1 and E2 viral envelope proteins. HCV entry requires interaction with a number of receptors which include CD81, scavenger receptor B1 (SR-B1) and the tight junction proteins, claudin 1 (CLDN1) and occludin (OCLN). Since the E2 glycoprotein is reported to interact directly with cellular receptors, it is an attractive target for neutralisation. The present study focuses on the establishment and characterisation of entry inhibitors as antivirals for HCV. The thesis is presented in three chapters: Chapter 1- ‘Introduction’, provides a brief overview on HCV genotypes, genome organisation, life cycle including details on the entry process and therapies used for the treatment of HCV. Chapter 2 describes the generation of monoclonal antibodies (mAbs) against HCV envelope proteins as potent anti-viral agents for the prevention of HCV infection. Data on the identification and characterization of the neutralizing epitopes of HCV envelope proteins have been presented. Chapter 3 includes isolation of entry inhibitors of HCV from natural sources and identification and characterization of the active components exhibiting antiviral property. A number of studies have reported the role of neutralizing antibodies in the course of HCV infection and emerging data suggest protective effect of antibodies against HCV infection. Most of the ongoing studies are based on HCV genotype 1a which is prevalent globally. However in India, the prevalent genotype is 3a. Therefore, we established a panel of mAbs against HCV-LPs comprising of core-E1-E2 derived from genotype 3a as described in chapter 2. HCV-LP based system has been used in this study since it mimics the biophysical conformation, morphology and antigenic properties of the native… Advisors/Committee Members: Karande, Anjali A.

Subjects/Keywords: Hepatitis C Virus; Monoclonal Antibodies; Hepatitis C Virus Infection; Hepatitis C Virus Entry; HCV Small Molecule Inhibitors; Hepatitis C Virus Treatment; HCV Treatment; Rutin; Hepatitis C Virus E2 Protein; Biochemistry

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Bose, M. (2016). Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors. (Thesis). Indian Institute of Science. Retrieved from http://etd.iisc.ernet.in/handle/2005/2920 ; http://etd.ncsi.iisc.ernet.in/abstracts/3782/G27861-Abs.pdf

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Bose, Mihika. “Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors.” 2016. Thesis, Indian Institute of Science. Accessed February 25, 2020. http://etd.iisc.ernet.in/handle/2005/2920 ; http://etd.ncsi.iisc.ernet.in/abstracts/3782/G27861-Abs.pdf.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Bose, Mihika. “Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors.” 2016. Web. 25 Feb 2020.

Vancouver:

Bose M. Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors. [Internet] [Thesis]. Indian Institute of Science; 2016. [cited 2020 Feb 25]. Available from: http://etd.iisc.ernet.in/handle/2005/2920 ; http://etd.ncsi.iisc.ernet.in/abstracts/3782/G27861-Abs.pdf.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Bose M. Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors. [Thesis]. Indian Institute of Science; 2016. Available from: http://etd.iisc.ernet.in/handle/2005/2920 ; http://etd.ncsi.iisc.ernet.in/abstracts/3782/G27861-Abs.pdf

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Indian Institute of Science

28. Bose, Mihika. Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors.

Degree: 2016, Indian Institute of Science

URL: http://hdl.handle.net/2005/2920

► Hepatitis C virus (HCV) represents a global health threat. HCV is a blood-borne positive-strand RNA virus belonging to the Flaviviridae family that infects ~160 million… (more)

▼ Hepatitis C virus (HCV) represents a global health threat. HCV is a blood-borne positive-strand RNA virus belonging to the Flaviviridae family that infects ~160 million people worldwide. About 70% of infected individuals fail to clear the virus and subsequently develop chronic hepatitis, frequently leading to liver cirrhosis and in some cases hepatocellular carcinoma. Therapeutic options for HCV infection are still limited and a protective vaccine is not yet available. Currently available therapies include administration of pegylated alpha interferon in combination with ribavirin. The recently approved protease inhibitors Boceprevir and Telaprevir are also included in the treatment regimen. However, limitations to the treatment with direct-acting antivirals (DAAs) are associated with severe side effects and low sustained virological response (SVR) rates that vary depending on the virus and host genotype. The replication step of the viral life cycle is mostly targeted by majority of DAAs. Recent findings have suggested that a combination of entry inhibitors together with DAAs exhibit a synergistic effect in the treatment of HCV. Therefore, identification of efficient HCV entry inhibitors is of high priority In vitro studies have shown that HCV attachment and subsequent entry into the host cells is mediated by E1 and E2 viral envelope proteins. HCV entry requires interaction with a number of receptors which include CD81, scavenger receptor B1 (SR-B1) and the tight junction proteins, claudin 1 (CLDN1) and occludin (OCLN). Since the E2 glycoprotein is reported to interact directly with cellular receptors, it is an attractive target for neutralisation. The present study focuses on the establishment and characterisation of entry inhibitors as antivirals for HCV. The thesis is presented in three chapters: Chapter 1- ‘Introduction’, provides a brief overview on HCV genotypes, genome organisation, life cycle including details on the entry process and therapies used for the treatment of HCV. Chapter 2 describes the generation of monoclonal antibodies (mAbs) against HCV envelope proteins as potent anti-viral agents for the prevention of HCV infection. Data on the identification and characterization of the neutralizing epitopes of HCV envelope proteins have been presented. Chapter 3 includes isolation of entry inhibitors of HCV from natural sources and identification and characterization of the active components exhibiting antiviral property. A number of studies have reported the role of neutralizing antibodies in the course of HCV infection and emerging data suggest protective effect of antibodies against HCV infection. Most of the ongoing studies are based on HCV genotype 1a which is prevalent globally. However in India, the prevalent genotype is 3a. Therefore, we established a panel of mAbs against HCV-LPs comprising of core-E1-E2 derived from genotype 3a as described in chapter 2. HCV-LP based system has been used in this study since it mimics the biophysical conformation, morphology and antigenic properties of the native… Advisors/Committee Members: Karande, Anjali A.

Subjects/Keywords: Hepatitis C Virus; Monoclonal Antibodies; Hepatitis C Virus Infection; Hepatitis C Virus Entry; HCV Small Molecule Inhibitors; Hepatitis C Virus Treatment; HCV Treatment; Rutin; Hepatitis C Virus E2 Protein; Biochemistry

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Bose, M. (2016). Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors. (Thesis). Indian Institute of Science. Retrieved from http://hdl.handle.net/2005/2920

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Bose, Mihika. “Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors.” 2016. Thesis, Indian Institute of Science. Accessed February 25, 2020. http://hdl.handle.net/2005/2920.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Bose, Mihika. “Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors.” 2016. Web. 25 Feb 2020.

Vancouver:

Bose M. Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors. [Internet] [Thesis]. Indian Institute of Science; 2016. [cited 2020 Feb 25]. Available from: http://hdl.handle.net/2005/2920.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Bose M. Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors. [Thesis]. Indian Institute of Science; 2016. Available from: http://hdl.handle.net/2005/2920

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

29. Dakić Zoran. Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C.

Degree: 2017, University of Novi Sad

URL: http://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija145923723116719.pdf?controlNumber=(BISIS)100362&fileName=145923723116719.pdf&id=5188&source=OATD&language=en ; http://www.cris.uns.ac.rs/record.jsf?recordId=100362&source=OATD&language=en

►

Adekvatni nadzor nad zaraznim bolestima predstavlja aktuelni izazov ne samo kod nas već i u razvijenim zemljama. Savremeni epidemiološki nadzor nad zaraznim bolestima zasniva… (more)

▼

Adekvatni nadzor nad zaraznim bolestima predstavlja aktuelni izazov ne samo kod nas već i u razvijenim zemljama. Savremeni epidemiološki nadzor nad zaraznim bolestima zasniva se na odgovarajućim definicijama slučaja. Njihova osnovna funkcija je olakšavanje prepoznavanja određenih bolesti i njihovo registrovanje na jednoobrazan način. Definisanje slučajeva zaraznih bolesti nije jednostavno, jer uključuje kliničke, epidemiološke i laboratorijske parametre, uz istovremeno očekivanje visoke senzitivnosti i specifičnosti. Ciljevi istraživanja su bili da se utvrdi primenljivost definicija slučaja hepatitisa B i C na Klinici za infektivne bolesti Kliničkog centra Vojvodine, te da se utvrdi senzitivnost i specifičnost primenjenih definicija slučaja hepatitisa B i C. Uz postojeći dijagnostički algoritam Klinike za infektivne bolesti Kliničkog centra Vojvodine, uvedena su tri seta definicija hepatitisa B i C: Evropskog centra za prevenciju i kontrolu bolesti (ECDC) iz 2008. i 2012.godine kao i američkih Centara za kontrolu bolesti (CDC) iz 2012. godine. Istraživanje je sprovedeno na Klinici za infektivne bolesti Kliničkog centra Vojvodine i tokom 12 meseci, u skladu sa predloženim definicijama slučaja, identifikovano je 150 ispitanika obolelih od hepatitisa B i C. Utvrđene su sledeće činjenice: preporučene definicije slučaja su primenljive u Republici Srbiji za laboratorijske i kliničke kriterijume, dok uključivanje epidemiološke povezanosti u definicije slučaja ima malo praktičnog značaja za prijavljivanje hepatitisa; definicije slučaja koje uključuju i obavezno prisustvo kliničkih kriterijuma (najčešće definicije verovatnog slučaja) imaju nisku senzitivnost, a visoku specifičnost, kao posledica prisustva infekcije i u odsustvu bilo kakvih kliničkih manifestacija; definicije slučaja koje se zasnivaju samo na laboratorijskim kriterijumima imaju maksimalnu senzitivnost i specifičnost.

Adequate surveillance of communicable diseases is the actual challenge, not only in our country but also in developed countries. Modern epidemiological surveillance of communicable diseases is based on the appropriate case definitions. Their main purpose of them is to facilitate the recognition of certain diseases and their registration in a uniform manner. Case definition of communicable diseases is not easy, because it involves clinical, epidemiological and laboratory parameters, along with the expectated high sensitivity and specificity.The objectives of the study were to determine the applicability of the casedefinitions for hepatitis B and C in the Clinic for Infectious Diseases of the Clinical Center of Vojvodina and to determine the sensitivity and specificity of the applied definition of cases of hepatitis B and C. In addition to existing diagnostic algorithm of the Clinic for Infectious Diseases, three sets of hepatitis B and C case definitions were introduced: the European Centre for Disease Prevention and Control in 2008 and 2012 as well as the US Centers for Disease Control in 2012. The…

Advisors/Committee Members: Đurić Predrag, Fabri Milotka, Dragovac Gorana, Kocić Biljana, Turkulov Vesna, Dugandžija Tihomir, Petrović Vladimir.

Subjects/Keywords: hepatitis B; hepatitis C; dijagnoza; epidemiologija; javno zdravlje; Hepatitis B; Hepatitis C; Diagnosis; Epidemiology; Public Health

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Zoran, D. (2017). Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C. (Thesis). University of Novi Sad. Retrieved from http://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija145923723116719.pdf?controlNumber=(BISIS)100362&fileName=145923723116719.pdf&id=5188&source=OATD&language=en ; http://www.cris.uns.ac.rs/record.jsf?recordId=100362&source=OATD&language=en

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Zoran, Dakić. “Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C.” 2017. Thesis, University of Novi Sad. Accessed February 25, 2020. http://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija145923723116719.pdf?controlNumber=(BISIS)100362&fileName=145923723116719.pdf&id=5188&source=OATD&language=en ; http://www.cris.uns.ac.rs/record.jsf?recordId=100362&source=OATD&language=en.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Zoran, Dakić. “Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C.” 2017. Web. 25 Feb 2020.

Vancouver:

Zoran D. Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C. [Internet] [Thesis]. University of Novi Sad; 2017. [cited 2020 Feb 25]. Available from: http://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija145923723116719.pdf?controlNumber=(BISIS)100362&fileName=145923723116719.pdf&id=5188&source=OATD&language=en ; http://www.cris.uns.ac.rs/record.jsf?recordId=100362&source=OATD&language=en.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Zoran D. Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C. [Thesis]. University of Novi Sad; 2017. Available from: http://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija145923723116719.pdf?controlNumber=(BISIS)100362&fileName=145923723116719.pdf&id=5188&source=OATD&language=en ; http://www.cris.uns.ac.rs/record.jsf?recordId=100362&source=OATD&language=en

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

30. Celina Maria Pereira de Moraes Soares. Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005.

Degree: 2006, Universidade Católica de Santos

URL: http://biblioteca.unisantos.br/tede/tde_busca/arquivo.php?codArquivo=4

► Esta pesquisa é um estudo transversal, com método quantitativo e análise de prevalência dos dados. Apresenta como objetivo estimar a soroprevalência das hepatites virais B… (more)

▼ Esta pesquisa é um estudo transversal, com método quantitativo e análise de prevalência dos dados. Apresenta como objetivo estimar a soroprevalência das hepatites virais B e C em pacientes infectados pelo HIV. A justificativa deste estudo evidencia-se nas atuais doenças sexualmente transmissíveis (HIV e HBV) e de transmissão sanguínea (HIV, HBV e HCV), por protagonizar substancialmente o panorama do enfrentamento mundial em saúde pública. Santos/SP, cidade litorânea e turística, onde está localizado o maior porto marítimo da América Latina, com um grande número de homens que fazem sexo com homens, mulheres trabalhadores do sexo e usuários de drogas injetáveis, além de apresentar população flutuante de turistas, trabalhadores diretos e indiretos na atividade portuária. Neste sentido constrói um perfil humano relevante que caracteriza a elaboração do atual estudo. A coleta de dados foi realizada na população de pacientes matriculados no Centro de Referência em Aids CRAIDS, Santos, SP. A amostra foi constituída por 1438 pessoas, no período de fevereiro de 2004 a fevereiro de 2005. A análise nos prontuários foi realizada selecionando resultados de marcadores sorológicos para as hepatite B (HBsAg e anti-HBs) e hepatite C (anti-HCV), pela técnica de ELISA, além dos exames sorológicos de menor contagem de linfócitos T CD4+ e maior contagem de carga viral para o HIV, considerando as variáveis: sexo, idade, escolaridade, estado civil, forma de contaminação. Os resultados demonstraram que na população dos 1438 indivíduos HIV+, 54.6% eram do sexo masculino e 45.4% do feminino. Em relação à idade, 71% estavam entre 30 e 49 anos e 54.3% com nível de escolaridade no ensino fundamental. A contagem de linfócitos CD4+ revelou 43.7% com níveis abaixo de 200 células /mm. Considerando a soroprevalência dos marcadores HBsAg, anti-HBs, Anti-HCV e fatores de risco para essas doenças obtivemos uma prevalência global de HBsAg de 7.4% e 23.5% para o anti-HCV. As variáveis que apresentaram associação com o HBV foram: idade, baixos níveis de células T CD4+, homossexualidade masculina e UDI; para HCV: idade, sexo, escolaridade de nível superior e UDI. Advisors/Committee Members: Marcos Montani Caseiro.

Subjects/Keywords: soroprevalência; hepatitis B; hepatitis C; HIV; fatores de risco; SAUDE COLETIVA

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Soares, C. M. P. d. M. (2006). Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005. (Thesis). Universidade Católica de Santos. Retrieved from http://biblioteca.unisantos.br/tede/tde_busca/arquivo.php?codArquivo=4

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Soares, Celina Maria Pereira de Moraes. “Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005.” 2006. Thesis, Universidade Católica de Santos. Accessed February 25, 2020. http://biblioteca.unisantos.br/tede/tde_busca/arquivo.php?codArquivo=4.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Soares, Celina Maria Pereira de Moraes. “Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005.” 2006. Web. 25 Feb 2020.

Vancouver:

Soares CMPdM. Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005. [Internet] [Thesis]. Universidade Católica de Santos; 2006. [cited 2020 Feb 25]. Available from: http://biblioteca.unisantos.br/tede/tde_busca/arquivo.php?codArquivo=4.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Soares CMPdM. Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005. [Thesis]. Universidade Católica de Santos; 2006. Available from: http://biblioteca.unisantos.br/tede/tde_busca/arquivo.php?codArquivo=4

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

		in
And / Or
		in
And / Or
		in
And / Or
		in

Open Access Theses and Dissertations